key: cord-0950639-9mpeuma4
authors: Bauer, Wolfgang; Ulke, Jannis; Galtung, Noa; Strasser-Marsik, Leonore Claudia; Neuwinger, Nick; Tauber, Rudolf; Somasundaram, Rajan; Kappert, Kai
title: Role of Cell Adhesion Molecules for Prognosis of Disease Development of Patients With and Without COVID-19 in the Emergency Department
date: 2021-01-27
journal: J Infect Dis
DOI: 10.1093/infdis/jiab042
sha: 271150f97d84228677e2a8f0d8ec5d8b7a638f02
doc_id: 950639
cord_uid: 9mpeuma4

nan

To the Editor-While the coronavirus disease 2019 (COVID-19) is mostly characterized by mild symptoms, some infections provoke a cytokine storm, leading to septic shock and multiorgan failure (MOF) [1] [2] [3] . A severe course of the disease may be accompanied by coagulopathy and endotheliopathy, leading to thrombotic and microvascular complications [4] . Therefore, endothelial markers [4] [5] [6] might predict the outcome of COVID-19 patients an early stage after diagnosis, with direct impact on decisions regarding therapy requirements.

With great interest we have read the recent articles by Tong et al and Li et al examining blood levels of endothelial cell adhesion molecules (CAMs) in COVID-19 patients [5, 7] . They showed that vascular CAM-1 (VCAM-1), intercellular CAM-1 (ICAM-1), and platelet endothelial CAM-1 (PECAM-1) were elevated in patients with mild disease and strongly elevated in severe cases compared to an uninfected cohort. In further studies, COVID-19 patients who were later admitted to the intensive care unit (ICU) had increased soluble E-selectin (sE-selectin) plasma levels at hospital admission compared to hospitalized COVID-19 patients in conventional wards [6] . Moreover, elevated levels of soluble P-selectin (sP-selectin) were shown in ICU patients compared with non-ICU patients [4] . Indeed, CAMs critically involved in inflammatory responses may predict organ dysfunction in septic patients [8] . However, this has not been evaluated in detail in comparison to patients with clinically comparable symptoms in the emergency department (ED) but ruled-out severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, that is non-COVID-19 infectious diseases. Importantly, it has not yet been fully elucidated whether changes in CAMs are superior when compared to traditional biomarkers.

Therefore, we set out to measure CAM levels with regard to prognosis of disease progression (subsequent ICU admission, MOF, mortality) in ED patients. We prospectively enrolled 69 patients presenting to the ED between 20 March and 6 June 2020 with clinically suspected SARS-CoV-2 infections and isolated serum samples for further investigation. Chest computed tomography along with polymerase chain reaction (PCR) assays of pharyngeal swab samples were performed, resulting in 19 patients diagnosed with COVID-19 and 46 patients in whom COVID-19 was ruled out. Additionally, 4 patients had inconclusive findings and were removed from the analysis. The routine biomarkers lactate, C-reactive protein (CRP), and procalcitonin (PCT) were determined immediately as standard of care; ICAM-1, VCAM-1, sP-selectin, sL-selectin, and sE-selectin were measured using enzymelinked immunosorbent assays (ELISAs; all R&D Systems, except sL-selectin, Invitrogen) (Table1).

The disease course was assessed regarding the clinical endpoints (1) admission to the ICU, and (2) MOF (defined by the clinical need for organ replacement of at least 2 organ systems within the SOFA [Sequential Organ Failure Assessment] score [9] ), within 72 hours after presentation. We calculated P values and compared the area under the receiver operating characteristic curve (AUROC) with 95% confidence intervals (CI) for predicting the end points (Table 1) .

Serum concentration of VCAM-1 was significantly higher in COVID-19 patients than in non-COVID-19 patients (2095 vs 1367 pg/mL, P < .01). In contrast, sP-selectin concentration was significantly lower in COVID-19 patients (57.1 vs 84.2 ng/mL, P = .03).

Among COVID-19 patients, serum sL-selectin displayed a significant decrease in patients developing MOF within 72 hours compared to non-MOF patients (1947 ng/mL vs 1358 ng/mL, P = .04), and also showed the highest AUROC (0.85) as compared to lactate (0.79), CRP (0.70), and PCT (0.75).

In patients requiring ICU treatment, interestingly, no significant differences in serum CAM concentrations were observed between COVID-19 and non-COVID-19.

To summarize, our study assessed the association of serum CAM levels at an early stage of suspected COVID-19, that is when patients presented to the ED. We show that VCAM-1 was not only elevated in COVID-19 patients compared to uninfected/ healthy controls [5] , but also compared to non-COVID-19 patients presenting with suspicion of and symptoms comparable to COVID-19 but ruled-out SARS-CoV-2 infection. Furthermore, sP-selectin concentration was significantly lower in COVID-19 patients with a positive correlation to platelet counts (R = 0.47, P < .0001, data not shown) with lower platelets found in COVID-19 compared to non-COVID-19 patients (191/nL vs 240/nL, P = .02; data not shown). This is in accordance with the concept that thrombocytopoiesis may be affected by COVID-19 [10] . While the sP-selectin reduction seems to be associated with COVID-19, it does not predict further disease outcome, rather representing a disease bystander, at least at early stages of the disease. Our data further suggest sL-selectin as a valuable prognostic biomarker in COVID-19 patients (P = .04, AUROC = 0.85) with regard to subsequent MOF, which performs better than traditional biomarkers, including lactate. Our results might add to the diagnostic biomarker repertoire, characterizing the early inflammatory immune response, that is Table 1 

Serum protein profiling reveals a specific upregulation of the immunomodula tory protein progranulin in COVID-19

Cytokine storms: understanding COVID-19

COVID-19 and multiorgan failure: a narrative review on potential mechanisms

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients

Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients

Serum levels of soluble platelet endothelial cell adhesion molecule 1 in COVID-19 patients are associated with disease severity

Markers of endothelial damage in organ dysfunction and sepsis

The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Mechanism of thrombocytopenia in COVID-19 patients